We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals
Read MoreHide Full Article
Novocure Limited (NVCR - Free Report) announced meeting the primary endpoint of overall survival (OS) in a late-stage study, which evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with chemotherapy regimen as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. Shares of the company gained 49% on Monday in response to the encouraging news.
TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The phase III PANOVA-3 evaluated the efficacy and safety of TTFields therapy in combination with standard-of-care (SoC) chemotherapy (gemcitabine and nab-paclitaxel) to treat pancreatic cancer patients. The enrolled patient population was randomized equally into two arms to receive either the combo regimen or SoC chemotherapy alone (control) and followed for atleast 18 months.
Pancreatic cancer is one of the deadliest cancers and the third leading cause of cancer-related deaths in the United States. While overall cancer rates remaining stable or declining, pancreatic cancer incidence and mortality are rising, with around 67,000 new cases in the United States annually and a five-year survival rate of only 13%. This represents a significant unmet medical need.
Year to date, shares of Novocure have skyrocketed 99.9% against the industry’s 7% decline.
Per the data readout, pancreatic adenocarcinoma patients treated with TTFields therapy concomitant with SoC chemotherapy experienced a median OS of 16.20 months compared with 14.16 months in the control arm, demonstrating a statistically significant 2-month improvement in survival benefit. Consequently, PANOVA-3 became the first and only phase III study to demonstrate a statistically significant OS benefit, specifically in unresectable, locally advanced pancreatic cancer.
Novocure further reported that the survival rate benefit for patients treated with TTFields therapy increased over time, witnessing a 13% improvement in the OS rate at 12 months and a 33% improvement in the survival rate at 24 months. Additionally, the combo therapy was also overall well-tolerated in the study with a safety profile consistent with prior clinical studies.
Detailed results from the phase III PANOVA-3 study will be presented at an upcoming medical conference. Based on the encouraging phase III results, Novocure plans to file regulatory applications seeking the approval of TTFields therapy to treat unresectable, locally advanced pancreatic adenocarcinoma in the United States, the European Union, Japan and other key geographies.
NVCR’s Ongoing Pipeline Development Programs
Please note that an ongoing phase II PANOVA-4 study is currently evaluating the use of TTFields therapy in combination with Roche’s (RHHBY - Free Report) Tecentriq (atezolizumab) and SoC chemotherapy to treat metastatic pancreatic cancer. Enrollment in the study has already been completed. Novocure expects to share topline data from the PANOVA-4 study in 2026.
The primary endpoint of this mid-stage study is the disease control rate. Key secondary endpoints include OS, progression-free survival, one-year survival rate, objective response rate, progression-free survival at six months, duration of response and toxicity.
Several other mid-to-late-stage studies evaluating TTFields therapy in combinations or as monotherapy across a variety of cancer indications are also underway.
Roche’s blockbuster immuno-oncology drug, Tecentriq, is currently approved in the United States, the European Union and several other countries to treat some of the most aggressive and difficult-to-treat forms of cancer, including advanced lung cancer, urothelial cancer and breast cancer.
Roche’s extensive development program for Tecentriq includes multiple ongoing and planned phase III studies across lung, genitourinary, skin, breast, gastrointestinal, gynecological and head and neck cancers.
NVCR’s Zacks Rank & Stocks to Consider
Novocure currently carries a Zacks Rank #3 (Hold).
In the past 60 days, Pfizer’s earnings estimates have risen from $2.62 to $2.91 per share for 2024, while that for 2025 has increased from $2.84 to $2.91. PFE shares have lost 10.3% year to date.
Pfizer’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 74.50%.
In the past 60 days, Gilead Sciences’ earnings estimates have risen from $3.79 to $4.32 per share for 2024, while that for 2025 has increased from $7.24 to $7.38. GILD shares have risen 16.1% year to date.
Gilead Sciences’ earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 15.46%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals
Novocure Limited (NVCR - Free Report) announced meeting the primary endpoint of overall survival (OS) in a late-stage study, which evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with chemotherapy regimen as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. Shares of the company gained 49% on Monday in response to the encouraging news.
TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The phase III PANOVA-3 evaluated the efficacy and safety of TTFields therapy in combination with standard-of-care (SoC) chemotherapy (gemcitabine and nab-paclitaxel) to treat pancreatic cancer patients. The enrolled patient population was randomized equally into two arms to receive either the combo regimen or SoC chemotherapy alone (control) and followed for atleast 18 months.
Pancreatic cancer is one of the deadliest cancers and the third leading cause of cancer-related deaths in the United States. While overall cancer rates remaining stable or declining, pancreatic cancer incidence and mortality are rising, with around 67,000 new cases in the United States annually and a five-year survival rate of only 13%. This represents a significant unmet medical need.
Year to date, shares of Novocure have skyrocketed 99.9% against the industry’s 7% decline.
Image Source: Zacks Investment Research
NVCR’s TTFields Therapy Shows Significant Survival Benefits
Per the data readout, pancreatic adenocarcinoma patients treated with TTFields therapy concomitant with SoC chemotherapy experienced a median OS of 16.20 months compared with 14.16 months in the control arm, demonstrating a statistically significant 2-month improvement in survival benefit. Consequently, PANOVA-3 became the first and only phase III study to demonstrate a statistically significant OS benefit, specifically in unresectable, locally advanced pancreatic cancer.
Novocure further reported that the survival rate benefit for patients treated with TTFields therapy increased over time, witnessing a 13% improvement in the OS rate at 12 months and a 33% improvement in the survival rate at 24 months. Additionally, the combo therapy was also overall well-tolerated in the study with a safety profile consistent with prior clinical studies.
Detailed results from the phase III PANOVA-3 study will be presented at an upcoming medical conference. Based on the encouraging phase III results, Novocure plans to file regulatory applications seeking the approval of TTFields therapy to treat unresectable, locally advanced pancreatic adenocarcinoma in the United States, the European Union, Japan and other key geographies.
NVCR’s Ongoing Pipeline Development Programs
Please note that an ongoing phase II PANOVA-4 study is currently evaluating the use of TTFields therapy in combination with Roche’s (RHHBY - Free Report) Tecentriq (atezolizumab) and SoC chemotherapy to treat metastatic pancreatic cancer. Enrollment in the study has already been completed. Novocure expects to share topline data from the PANOVA-4 study in 2026.
The primary endpoint of this mid-stage study is the disease control rate. Key secondary endpoints include OS, progression-free survival, one-year survival rate, objective response rate, progression-free survival at six months, duration of response and toxicity.
Several other mid-to-late-stage studies evaluating TTFields therapy in combinations or as monotherapy across a variety of cancer indications are also underway.
Novocure Limited Price and Consensus
NovoCure Limited price-consensus-chart | NovoCure Limited Quote
Roche’s blockbuster immuno-oncology drug, Tecentriq, is currently approved in the United States, the European Union and several other countries to treat some of the most aggressive and difficult-to-treat forms of cancer, including advanced lung cancer, urothelial cancer and breast cancer.
Roche’s extensive development program for Tecentriq includes multiple ongoing and planned phase III studies across lung, genitourinary, skin, breast, gastrointestinal, gynecological and head and neck cancers.
NVCR’s Zacks Rank & Stocks to Consider
Novocure currently carries a Zacks Rank #3 (Hold).
Some better-ranked pharma stocks are Pfizer (PFE - Free Report) and Gilead Sciences (GILD - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, Pfizer’s earnings estimates have risen from $2.62 to $2.91 per share for 2024, while that for 2025 has increased from $2.84 to $2.91. PFE shares have lost 10.3% year to date.
Pfizer’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 74.50%.
In the past 60 days, Gilead Sciences’ earnings estimates have risen from $3.79 to $4.32 per share for 2024, while that for 2025 has increased from $7.24 to $7.38. GILD shares have risen 16.1% year to date.
Gilead Sciences’ earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 15.46%.